Royalty Pharma plc
RPRX
|
News
|
$28.17
1.0%
0.99%
1.8M
|
Health Technology
(0.0% 1d) (-7.5% 1m) (-22.0% 1y) (2.2% 2d) (2.0% 3d) (-0.3% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-15
Market Cap: $ 12,583,299,978
http://www.royaltypharma.com
Sec Filling | Patents | 51 employees
(US) Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.
hiv royalties msa profitable
add to watch list Paper trade email alert is off
Press-releases
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
Published: 2024-04-19 (Crawled : 12:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.83%
H: 1.35%
C: 1.2%
RPRX | News | $28.17 1.0% 0.99% 1.8M
|
Health Technology
|
| O: 1.07%
H: 1.22%
C: 1.11%
first pharma royalty financial results
Royalty Pharma Declares Second Quarter 2024 Dividend
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.28%
C: -0.16%
RPRX | News | $28.17 1.0% 0.99% 1.8M
|
Health Technology
|
| O: -1.5%
H: 0.84%
C: 0.25%
pharma royalty
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
Published: 2024-02-28 (Crawled : 21:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.56%
H: 0.12%
C: -0.38%
RPRX | News | $28.17 1.0% 0.99% 1.8M
|
Health Technology
|
| O: 0.29%
H: 0.08%
C: -1.17%
pharma conference health care royalty
Royalty Pharma Reports Q4 and Full Year 2023 Results
Published: 2024-02-15 (Crawled : 12:30) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.19%
H: 1.6%
C: 1.24%
RPRX | News | $28.17 1.0% 0.99% 1.8M
|
Health Technology
|
| O: 1.26%
H: 3.99%
C: 1.21%
pharma year royalty results
Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
Published: 2024-01-30 (Crawled : 21:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.49%
H: 0.14%
C: -0.94%
RPRX | News | $28.17 1.0% 0.99% 1.8M
|
Health Technology
|
| O: 0.07%
H: 0.44%
C: -1.08%
pharma year royalty financial results
Royalty Pharma Announces Dividend Increase
Published: 2024-01-19 (Crawled : 13:30) - royaltypharma.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.67%
H: 0.0%
C: 0.0%
RPRX | News | $28.17 1.0% 0.99% 1.8M
|
Health Technology
|
| O: 0.57%
H: 3.21%
C: 3.09%
pharma royalty
Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-08 (Crawled : 12:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.47%
H: 0.0%
C: 0.0%
RPRX | News | $28.17 1.0% 0.99% 1.8M
|
Health Technology
|
| O: 0.0%
H: 1.84%
C: 1.82%
pharma conference business update royalty
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
Published: 2023-11-27 (Crawled : 21:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
RPRX | News | $28.17 1.0% 0.99% 1.8M
|
Health Technology
|
| O: -0.04%
H: 0.39%
C: -0.15%
pharma conference royalty
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
Published: 2023-11-13 (Crawled : 13:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
RPRX | News | $28.17 1.0% 0.99% 1.8M
|
Health Technology
|
| O: -0.44%
H: 0.59%
C: 0.04%
pharma royalty teva program
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
Published: 2023-11-13 (Crawled : 13:30) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -0.92%
H: 4.53%
C: 2.56%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
RPRX | News | $28.17 1.0% 0.99% 1.8M
|
Health Technology
|
| O: -0.44%
H: 0.59%
C: 0.04%
pharma royalty teva program
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10